Sorrento Therapeutics (OTCMKTS:SRNE – Get Free Report) is anticipated to issue its resultson Friday, November 6th. Analysts expect Sorrento Therapeutics to post earnings of $0.42 per share and revenue of $18.23 million for the quarter.
Sorrento Therapeutics Stock Performance
Shares of OTCMKTS:SRNE opened at $0.00 on Thursday. Sorrento Therapeutics has a 52-week low of $0.00 and a 52-week high of $0.01.
Sorrento Therapeutics Company Profile
Sorrento Therapeutics, Inc is a biotechnology company focused on developing therapies for cancer, chronic pain and other serious medical conditions. The company has historically pursued treatments based on antibody therapeutics, cellular therapies and targeted drug-delivery technologies, with research and development centered primarily in the United States.
Sorrento’s development programs have included immuno-oncology and chimeric antigen receptor T-cell (CAR-T) therapies, as well as its Sofusa lymphatic drug-delivery platform.
Read More
- Five stocks we like better than Sorrento Therapeutics
- Why ExxonMobil and Chevron Reminded Investors to Keep it Simple
- Amazon Has Erased Its Earnings Sell-Off, But Is the Biggest Opportunity Still Ahead?
- onsemi’s AI Sales Surge 175%: Is a Stock Recovery Next?
- Energy Transfer’s Earnings Miss May Be Hiding Its Strongest Advantage
Receive News & Ratings for Sorrento Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sorrento Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
